Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients

By C. Marzolini, A. Telenti, L. Decosterd, Gilbert GREUB, J. Biollaz, T. Buclin. AIDS (London), 2001

919 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Polymorphism of human cytochrome P450 enzymes and its clinical impact (2009, result): “However, this study did not observe an association between efavirenz plasma drug levels and toxicity, which they had previously reported (Marzolini et al., 2001).”
The Cytochrome P450 2B6 (CYP2B6) Is the Main Catalyst of Efavirenz Primary and Secondary Metabolism: Implication for HIV/AIDS Therapy and Utility of Efavirenz as a Substrate Marker of CYP2B6 Catalytic Activity (2003, background): “at greater risk for development of drug resistance and treatment failure (Marzolini et al., 2001; Langmann et al., 2002), and those with plasma concentrations over 4 mg/l are at increased risk of CNS side effects (Marzolini et al.”
Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study (2004, background): “Severe depression, aggressive behaviour and paranoid or manic reactions may also occur and such side effects may reflect varying efavirenz plasma concentrations [4,6].”